Editorial

Abstract

Achondroplasia, the most common genetic cause of short stature, results from a gain-of-function mutation in the FGFR3 gene, impairing cartilage development and bone growth. It affects about 1 in 26,000–28,000 live births and is associated with limb shortening, spinal stenosis, and airway complications, though intelligence remains unaffected. Recent therapies, including C-type natriuretic peptide analogues (vosoritide, TransCon CNP) and FGFR3 inhibitors such as infigratinib, show promise in improving growth outcomes. However, these treatments are not curative and mainly reduce disease burden. Future approaches, including selective FGFR3 inhibitors and gene-editing technologies like CRISPR-Cas9, may offer potential curative strategies. This communication emphasizes the ongoing shift from symptom management to curative possibilities in pediatric achondroplasia care.